TITLE

Peginterferon α-2a alone or with lamivudine increased response rates more than lamivudine alone for HBeAg-positive chronic hepatitis B

PUB. DATE
January 2006
SOURCE
ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p5
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article focuses on a clinical study to compare the effectiveness of peginterferon α2a, and lamivudine, in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. 814 patients who had been positive for hepatitis B surface antigen (HBsAg) for age of 6 months were negative for antibodies to HBsAg and positive for HBeAg. At 24 weeks after stopping treatment, patients who received peginterferon α2a, alone or plus lamivudine, had higher rates of HBeAg seroconversion, suppression of HBV DNA levels, and combined response than did those who received lamivudine monotherapy.
ACCESSION #
19515983

 

Related Articles

  • Recombinant α-Interferon May be Efficacious in Acute Hepatitis B. Halevy, J.; Achiron, A.; Spiegel, D.; Nili, M.; Luboshits, J.; Yerushalmi, Y.; Theodor, E. // American Journal of Gastroenterology;Feb1990, Vol. 85 Issue 2, p210 

    Whereas, in chronic type B hepatitis, the therapeutic effect of α-interferon has been studied extensively, data on the effect of interferon on the course and prognosis of acute hepatitis B are scarce in the literature. We report a case of acute type B hepatitis complicated by life-threatening...

  • Sero-Epidemiology of Hepatitis B Surface Antigenaemia among Adult Nigerians with Clinical Features of Liver Diseases Attending a Primary-Care Clinic in a Resource-Constrained Setting of Eastern Nigeria. Uche Pascal Iloh, Gabriel; Obiora Ikwudinma, Austin // North American Journal of Medical Sciences;Apr2013, Vol. 5 Issue 4, p293 

    Background: Hepatitis-B infection is not commonly perceived as a serious medical problem in Nigeria. However, chronic hepatitis-B infection, which is a subject of global concern, may lead to lethal liver diseases. Aim: The study was to determine the sero-epidemiology of hepatitis-B surface...

  • Trial of (+ )-cyanidanol-3 in patients with hepatitis B chronic liver disease. Keeling, P. W. N.; Viola, L.; Anderson, M. G.; Marigold, J. H.; Macartney, J. C.; Paradinas, F. J.; Murray-Lyon, I. M.; Thompson, R. P. H. // Journal of the Royal Society of Medicine;Aug1986, Vol. 79 Issue 8, p460 

    A double-blind controlled trial of 12 months' treatment with (+)-cyanidanol-3 was carried out in 26 patients with chronic hepatitis B liver disease. Treatment did not improve liver blood tests nor histological appearances of the liver, but there was a trend towards reduction of serum titres of...

  • Evaluation of ISCOMs for Immunization Against Hepatitis B. Pandey, R. S.; Dixit, V. K. // Current Pharmaceutical Biotechnology;Nov2009, Vol. 10 Issue 7, p709 

    Immune stimulating complexes (ISCOMs) incorporating recombinant hepatitis B surface antigen (rHBsAg) were prepared for induction of humoral and cellular immunity by subcutaneous administration. Prepared ISCOMs were characterized for their size, shape, incorporation efficiency, zeta potential,...

  • The Enigma of Concurrent Hepatitis B Surface Antigen (HBsAg) and Antibodies to HBsAg. Gerlich, Wolfram H. // Clinical Infectious Diseases;5/1/2007, Vol. 44 Issue 9, p1170 

    The article comments on the article "Coexistence of Hepatitis B Surface Antigen (HBsAg) and Heterologous Subtype-Specific Antibodies to HBsAg among Patients with Chronic Hepatitis B Virus (HBV) Infection," by Ji-Ming Zhang and colleagues, published within the issue. It states that Hepatitis B is...

  • A Liver Transplant Recipient with an Infected Explanted Liver.  // Clinical Infectious Diseases;1/15/2005, Vol. 40 Issue 2, p279 

    This article presents information on the medical case of a liver transplant recipient with an infected explanted liver. 52-year-old Chinese man, who had immigrated to Portland, Oregon, from the Guandong Province in southern China 20 years earlier, underwent cadaveric liver transplantation to...

  • Entecavir was more effective than lamivudine in HbeAg-positive chronic hepatitis B: COMMENTARY. Reichen, Jürg // ACP Journal Club;Jul/Aug2006, Vol. 145 Issue 1, p18 

    The article presents the author's views on a study, which focuses on a comparison of the drugs entecavir and lamivudine for treatment of patients infected with HbeAg-positive chronic hepatitis B. The author states that patients with HBeAG-positive chronic hepatitis B should be prescribed an...

  • Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study. Hosaka, Tetsuya; Suzuki, Fumitaka; Kobayashi, Masahiro; Seko, Yuya; Kawamura, Yusuke; Sezaki, Hitomi; Akuta, Norio; Suzuki, Yoshiyuki; Saitoh, Satoshi; Arase, Yasuji; Ikeda, Kenji; Kobayashi, Mariko; Kumada, Hiromitsu // Journal of Gastroenterology;Aug2013, Vol. 48 Issue 8, p930 

    Background: Clearance of hepatitis B surface antigen (HBsAg) is considered the ultimate goal in chronic hepatitis B treatment. One treatment option is long-term nucleot(s)ide analog (NA) therapy. We followed a group of long-term NA therapy patients to evaluate the efficacy of this treatment in...

  • INDUCTION OF HUMORAL IMMUNE RESPONSE USING HUMAN INTERFERON ALPHA 2B AND RECOMBINANT ANTI-HEPATITIS B VACCINE IN ASYMPTOMATIC CARRIER PATIENTS OF HEPATITIS B VIRUS. Torres, J. A. Santiesteban; Griego, A. González; González, A. Alerm; Acosta, J. Acosta; González, V. E.; Castillo, E. García; Montenegro, A.; De León, O. Ponce // Revista VacciMonitor (Vacunología y Temas Afines);Oct2002, Vol. 11 Issue 4, p1 

    The clinical consequences of Hepatitis B Virus (HBV) are extremely variables. Approximaltity 5-10 % of adults exposed to HBV and the 90 % of perinatally infect children develop a chronic infection. The nature of chronic infection is also variable. The Asymptomatic Carrier State (ASC) can have...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics